ClinicalTrials.gg
Status unknownNCT03787563Updated Dec 26, 2018

Herbal Tea in the Treatment of Type 2 Diabetes Mellitus

An interventional study of Herbal Tea and Placebo Tea in Type 2 Diabetes Mellitus, sponsored by Composite Interceptive Med Science. Status unknown at 1 site in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-26.

Sponsored by Composite Interceptive Med Science · Not applicable, Interventional, and Supportive care

The sponsor has not verified this record recently (last verified Dec 2018), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Diabetes mellitus is a chronic disease caused by inherited and/or acquired deficiency in production of insulin by the pancreas, or by the ineffectiveness of the insulin produced. It has become a major healthcare problem in India. High-quality, low-cost solutions adapted to the local context are critical to addressing the current crisis in the management of diabetes. Herbal tea consists of tulsi, guava and stevia, which has glucose lowering properties.The aim of this trial is to study the effect of a herbal tea in the glycemic response in the early type 2 diabetes.

02

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Herbal Tea
  • Diabetes
03

In context

Diabetes Mellitus, Type 2

10,371 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,406 are open to participants now.

This study's planned enrollment of 10 is below the median of 80 across 8,350 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Composite Interceptive Med Science is the lead sponsor of 10 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adults aged over 18 years and having a diagnosis of diabetes and meeting one of the following criteria

  1. Fasting Plasma Glucose ≥126 mg/dL, fasting defined as no caloric intake for at least 8 hours, AND
  2. 2-h Post load Glucose ≥140 mg/dL during an OGTT. AND
  3. Glycosylated () ≥ 6.5 %.

Exclusion criteria

Exclusion Criteria:

Any one of the following

  1. Patients on Insulin therapy.
  2. Patients on oral hypoglycemic agents other than metformin
  3. Any history suggestive of micro vascular or macro vascular disease - coronary artery disease, stroke, peripheral artery disease or diabetes related retinal changes.
  4. Women in child bearing age unable to practice any form of
  5. Patients with diagnosis of Anaemia ( \<11 g/dl in Female and \<13 g/dl in Male)
  6. Impaired renal function; estimated glomerular function \<60mls/min/1.73m2.
  7. Known history of any chronic illness taking regular pharmacological agents.
  8. Blood pressure fluctuations exceeding 20 mmHg on 2 subsequent clinic visits or known history of hypotension or bradycardia in last 6 months or taking 3 or more antihypertensive medications regularly in the last 6 weeks
  9. Known history of autonomic dysfunction like diabetic autonomic neural imbalance or neuropathy
  10. Participating in another clinical trial with an active intervention or drug or device with last dose taken within 60 days.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
10 participants (estimated)

Study arms

  • Active comparator
    Active Herbal tea

    One tea bag infusion three times a day each before breakfast, lunch and dinner.

    Drug: Herbal Tea

  • Placebo comparator
    Placebo Tea

    Similar looking tea bag infusion three times a day each before breakfast, lunch and dinner.

    Drug: Placebo Tea

Interventions

  • DrugHerbal Tea

    All participants will be given the intervention in an infusion tea bag. Participant will be instructed to take one tea bag three times a day at before breakfast, lunch and dinner meals. At the time of randomization both active and placebo infusion bag will be provided.There will be one day of washout period after 2 days on treatment.

  • DrugPlacebo Tea

    Similar looking inert placebo tea.

06

What researchers measure

Primary outcomes

  1. Fasting Plasma Glucose (FPG)

    Change from baseline in Fasting plasma glucose

    Time frame: 2 days and 5 days

  2. Oral Glucose Tolerance Test (OGTT)

    Change from baseline in OGTT

    Time frame: 2 days and 5 days

  3. Number of Subject with adverse events

    Adverse events is defined as any untoward medical occurrence that may not necessarily have a causal relationship with the treatment, but resulted in a dose reduction or discontinuation of treatment.

    Time frame: 2 days and 5 days

Secondary outcomes

  1. Flash Glucose Measurements

    Change from baseline in mean amplitude glycemic excursions measured by flash glucose monitoring sensor

    Time frame: 2 days and 5 days

07

Study locations

1 site
  • Health India Hospital
    Bangalore, Karnataka 560029, India
    • Thirumalesha RL, BAMS · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03787563
Lead sponsor
Composite Interceptive Med Science
Collaborators
Composite Interceptive Med-Science Laboratories Pvt Ltd
Responsible party
Sponsor
First posted
Dec 26, 2018
Start date
Jan 1, 2019 (estimated)
Primary completion
Jan 15, 2019 (estimated)
Completion
Jan 20, 2019 (estimated)
Last update
Dec 26, 2018

Study contacts

Sanjaya Chauhan, Pharm.D
Contact
drsanjayachauhan49@gmail.com
09611252350
HD Ramachandra Prabhu, MBBS, MD
principal investigator · Health India Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion